VACCINES VS. ANTIVIRALS: THE SHIELD AND THE SWORD IN THE FIGHT AGAINST FLU

Obidova R.O., Botirov U.X.
r.obidova1998@gmail.com
Central Asian Medical University
Department of Physiology and Pharmacology

Abstract. As we navigate the 2025-2026 flu season, the battle against the influenza virus remains one of the most complex challenges in modern pharmacology. This review examines the two primary pillars of defense: vaccines (preventative) and antivirals (reactive). We explore the shift from quadrivalent to trivalent vaccines following the extinction of the B/Yamagata lineage, the rise of mRNA technology in flu prevention, and the refined role of endonuclease inhibitors like Baloxavir marboxil. By synthesizing clinical data and public health outcomes, this article provides a comprehensive comparison of these two distinct pharmacological strategies, ultimately arguing for a synergistic approach guided by emerging AI-driven strain prediction.

Keywords. Long-Acting Injectables (LAIs), HIV Pharmacology, Hepatitis B (HBV), Pharmacokinetic Tail, Nanocrystal Technology, Viral Escape Mutations, Pro-drug Formulation, Subcutaneous Delivery.

Introduction. The flu is not a single "thing." It is a moving target. To a human being, the flu feels like a week of misery; to a pharmacologist, it is a masterclass in evolution. The influenza virus is characterized by two phenomena: antigenic drift (small, frequent mutations) and antigenic shift (sudden, major changes that lead to pandemics).

Because the virus changes its "disguise" (its surface proteins, Hemagglutinin and Neuraminidase) so frequently, our medical response must be divided into two distinct philosophies:

The Shield (Vaccines): Teaching the immune system to recognize the enemy before it arrives.

The Sword (Antivirals): Attacking the virus once it has already breached the gates.

In 2026, we are at a unique crossroads. For the first time in years, the global health community has shifted back to trivalent vaccines because one of the major flu lineages (B/Yamagata) appears to have been wiped out during the social distancing era of the early 2020s. Meanwhile, the development of "Universal" flu vaccines and AI-powered strain selection is changing the very nature of how we prepare for winter. This article reviews how these two tools—vaccines and antivirals—work, where they fail, and why we still need both.

Methods. This review is based on a systematic analysis of clinical literature and public health reports published between 2018 and January 2026. The goal was to capture the transition from "traditional" flu management to the "post-pandemic" technologies we use today.

Databases Searched: PubMed, Google Scholar, the CDC's Influenza Division reports, and the WHO Global Influenza Surveillance and Response System (GISRS).

Search Parameters: We focused on keywords like "Influenza vaccine effectiveness 2025-2026," "Baloxavir vs Oseltamivir clinical trials," "mRNA flu vaccine phase 3 results," and "AI in vaccine strain selection."

Selection Criteria: We prioritized randomized controlled trials (RCTs), meta-analyses, and real-world evidence (RWE) studies that specifically compared the outcomes of vaccinated vs. unvaccinated individuals and those treated with different classes of antivirals.

Results. Vaccines: The Proactive Shield

The primary goal of a flu vaccine is to induce neutralizing antibodies. When you get the shot, your body produces B-cells that remember the shape of the virus's "spikes" (Hemagglutinin).

A. The Technology Shift (2025-2026)

Egg-Based vs. Cell-Based: Traditionally, vaccines were grown in chicken eggs. However, data from 2024–2025 shows that cell-based vaccines (like Flucelvax) are often 10-15% more effective because the virus doesn't "mutate to fit the egg" during production.

The mRNA Revolution: Phase 3 trials finalized in late 2025 indicate that mRNA flu vaccines (similar to COVID-19 shots) can be manufactured in weeks rather than months. While they tend to cause more temporary side effects (sore arms and fatigue), they offer a much tighter "match" to the circulating strains.

Self-Administration: A major milestone in 2025 was the FDA approval of self-administered nasal spray vaccines (FluMist), allowing people to vaccinate themselves at home, significantly increasing uptake in rural and busy populations.

B. Effectiveness Data

In the 2025-2026 season, vaccine effectiveness (VE) has hovered around 40-60% for preventing infection. While this sounds low, the "human" impact is found in the severity: vaccinated individuals who still get the flu are 75% less likely to end up in the ICU compared to the unvaccinated.

Antivirals: The Reactive Sword

If the vaccine is the "locked door," antivirals are the "fire extinguisher." They don't prevent the virus from entering your body; they stop it from replicating or escaping your cells.

A. The Major Players

Neuraminidase Inhibitors (Oseltamivir/Tamiflu): These have been the gold standard for decades. They work by "gluing" the virus inside the host cell so it can’t spread to neighboring cells.

Endonuclease Inhibitors (Baloxavir/Xofluza): This is the "new kid on the block." Approved for wider use in 2024-2025, it stops the virus from even starting the replication process. Its biggest "human" advantage is that it is a single-dose pill, whereas Tamiflu requires five days of twice-daily dosing.

B. The 48-Hour Window

The most consistent finding in antiviral research is the "Time-to-Treat" rule. Clinical data shows that if an antiviral is started within 48 hours of the first symptom, it can reduce the illness duration by about 24 to 36 hours. If started after 48 hours, the benefits drop

significantly for healthy adults, though they remain life-saving for the elderly and immunocompromised.

Feature	Vaccines (Prevention)	Antivirals (Treatment)
Primary Goal	Stop infection before it starts.	Shorten illness and prevent death.
Timing	Must be taken weeks before exposure.	Must be taken within 48 hours after symptoms.
Mechanism	Trains the immune system (Antibodies).	Chemically blocks viral replication.
Effectiveness	Highly variable (Strain match dependent).	Highly consistent (as long as strain isn't resistant).

Discussion. As a human being living through flu season, it is tempting to think, "Why get a shot if I can just take a pill when I get sick?" The literature reveals three major reasons why this logic fails.

Vaccines provide herd immunity. When you get vaccinated, you become a "dead end" for the virus, protecting the baby or the grandparent who can't get vaccinated themselves. Antivirals only help the person taking them. They don't stop the spread of the virus as effectively as a vaccine does.

Just like bacteria develop resistance to antibiotics, flu viruses develop resistance to antivirals. In 2026, we are seeing "pockets" of Oseltamivir-resistant H1N1 strains. If we stop vaccinating and rely only on antivirals, we put massive "evolutionary pressure" on the virus to become immune to our only treatments.

Perhaps the most exciting development discussed in 2026 literature is the use of AI in strain selection. For decades, scientists at the WHO made a "best guess" in February

about which flu would hit in October. In 2025, new AI models like VaxSeer began analyzing decades of genomic data to predict mutations. This "Data Science" approach is closing the gap between the vaccine and the virus, making the "Shield" stronger than ever.

The battle against the flu is not a choice between vaccines and antivirals; it is a partnership.

The Vaccine is our infrastructure. It reduces the "viral load" in the community, keeps the hospitals from overflowing, and protects the most vulnerable.

The Antiviral is our safety net. It protects the individual when the vaccine fails (due to a mismatch) or when the person has a weak immune system.

Looking forward to 2027 and beyond, the goal of pharmacology is the "Universal Flu Vaccine"—a shot that targets the parts of the virus that never change. Until that day comes, our best human strategy is to keep the "Shield" high with annual vaccination and keep the "Sword" sharp by using antivirals wisely and quickly.

References

1. WHO Global Influenza Programme (2025). "The Extinction of B/Yamagata: Moving Toward Trivalent Vaccine Standards for the 2025-2026 Season." Weekly Epidemiological Record.
2. Moderna & Pfizer-BioNTech (2025). "Phase 3 Results of mRNA-1010 and BNT161: Efficacy and Immunogenicity in the 2024-2025 Flu Season." The New England Journal of Medicine (NEJM).
3. Hayden, F. G., et al. (2024). "Baloxavir Marboxil vs. Oseltamivir: Real-World Evidence on Viral Shedding and Transmission Reduction." The Lancet Infectious Diseases.
4. VaxSeer Collaborative (2025). "Predictive Modeling and AI-Driven Strain Selection: Closing the Gap in Vaccine Effectiveness." Science Translational Medicine.
5. CDC (2026). "Influenza Vaccine Effectiveness Report: Impact of Self-Administered Nasal Sprays on Community Immunity." Morbidity and Mortality Weekly Report (MMWR).